Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells

British Journal of Pharmacology

Volumn 145, Issue 8, 2005, Pages 1084-1092

  Barik, Jacques ^a   Dajas Bailador, Federico ^a,b   Wonnacott, Susan ^a  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

3H epibatidine binding sites; Acetylcholinesterase inhibitor; Galantamine; Intracellular Ca 2+; Neuronal nicotinic acetylcholine receptor; Noradrenaline release; Rivastigmine; SH SY5Y neuroblastoma cell line

Indexed keywords

ACETYLCHOLINESTERASE; CALCIUM ION; EPIBATIDINE; GALANTAMINE; MUSCARINIC RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; POTASSIUM CHLORIDE; RIVASTIGMINE;

ALLOSTERISM; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BINDING SITE; CALCIUM CELL LEVEL; CELL FUNCTION; CELL INTERACTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

BINDING SITES; CALCIUM; CELL LINE, TUMOR; CELL MEMBRANE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; GALANTAMINE; HUMANS; NEUROBLASTOMA; NICOTINE; NICOTINIC AGONISTS; POTASSIUM CHLORIDE; RECEPTORS, NICOTINIC; TIME FACTORS;

EID: 30544447736     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706278     Document Type: Article

References (45)

1. AGIS-TORRES, A., BALL, S.G. & VAUGHAN, F.F. (2002). Chronic treatment with nicotine or potassium attenuates depolarisation-evoked noradrenaline release from the human neuroblastoma SH-SY5Y. Neurosci. Lett., 331, 167-170.
2. ARIAS, E., ALES, E., GABILAN, N.H., CANO-ABAD, M.F., VILLARROYA, M., GARCIA, A.G. & LOPEZ, M.G. (2004). Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology, 46, 103-114.
3. BARNES, C.A., MELTZER, J., HOUSTON, F., ORR, G., MCGANN, K. & WENK, G.L. (2000). Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience, 99, 17-23.
4. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
5. BUISSON, B. & BERTRAND, D. (2001). Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function. J. Neurosci., 21, 1819-1829.
6. COYLE, J.T., PRICE, D.L. & DELONG, M.R. (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation. Science, 219, 1184-1190.
7. DAJAS-BAILADOR, F. & WONNACOTT, S. (2004). Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol. Sci., 25, 317-324.
8. 2+ signals and neurotransmitter release. Mol. Pharmacol., 64, 1217-1226.
9. 2+ stores. J. Neurochem., 81, 606-614.
10. DOWELL, C., OLIVERA, B.M., GARRETT, J.E., STAHELI, S.T., WATKINS, M., KURYATOV, A., YOSHIKAMI, D., LINDSTROM, J.M. & MCINTOSH, J.M. (2003). Alpha-conotoxin PIA is selective for alpha6 subunit-containing nicotinic acetylcholine receptors. J. Neurosci., 23, 8445-8452.
11. DUNCKLEY, T. & LUKAS, R.J. (2003). Nicotine modulates the expression of a diverse set of genes in the neuronal SH-SY5Y cell line. J. Biol. Chem., 278, 15633-15640.
12. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J. Neurochem., 47, 1948-1954.
13. GENTRY, C.L. & LUKAS, R.J. (2002). Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr. Drug Targets CNS Neurol. Disord., 1, 359-385.
14. GOPALAKRISHNAN, M., MOLINARI, E.J. & SULLIVAN, J.P. (1997). Regulation of human alpha4beta2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways. Mol. Pharmacol., 52, 524-534.
15. GOTTI, C. & CLEMENTI, F. (2004). Neuronal nicotinic receptors: from structure to pathology. Prog. Neurobiol., 74, 363-396.
16. HOGG, R.C. & BERTRAND, D. (2004). Nicotinic acetylcholine receptors as drug targets. Curr. Drug Targets CNS Neurol. Disord., 3, 123-130.
17. JIA, L., FLOTILDES, K., LI, M. & COHEN, B.N. (2003). Nicotine trapping causes the persistent desensitization of alpha4beta2 nicotinic receptors expressed in oocytes. J. Neurochem., 84, 753-766.
18. KATSURA, M., MOHRI, Y., SHUTO, K., HAI-DU, Y., AMANO, T., TSUJIMURA, A., SASA, M. & OHKUMA, S. (2002). Up-regulation of L-type voltage-dependent calcium channels after long term exposure to nicotine in cerebral cortical neurons. J. Biol. Chem., 277, 7979-7988.
19. KIHARA, T., SAWADA, H., NAKAMIZO, T., KANKI, R., YAMASHITA, H., MAELICKE, A. & SHIMOHAMA, S. (2004). Galantamine modulates nicotinic receptor and blocks A beta-enhanced glutamate toxicity. Biochem. Biophys. Res. Commun., 325, 976-982.
20. LADNER, C.J. & LEE, J.M. (1998). Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J. Neuropathol. Exp. Neurol., 57, 719-731.
21. LEVIN, E.D. & SIMON, B.B. (1998). Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berlin), 138, 217-230.
22. LOY, C. & SCHNEIDER, L. (2004). Galantamine for Alzheimer's disease. Cochrane Database. Syst. Rev., (CD001747).
23. LUKAS, R.J., NORMAN, S.A. & LUCERO, L. (1993). Characterisation of nicotinic acetylcholine receptors expressed by cells of the SH-SY5Y human neuroblastoma clonal line. Mol. Cell. Biol., 4, 1-12.
24. NASHMI, R., DICKINSON, M.E., MCKINNEY, S., JAREB, M., LABARCA, C., FRASER, S.E. & LESTER, H.A. (2003). Assembly of alpha4beta2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons. J. Neurosci., 23, 11554-11567.
25. NEWHOUSE, P.A., POTTER, A. & SINGH, A. (2004). Effects of nicotinic stimulation on cognitive performance. Curr. Opin. Pharmacol., 4, 36-46.
26. O'NEILL, M.J., MURRAY, T.K., LAKICS, V., VISANJI, N.P. & DUTY, S. (2002). The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr. Drug Targets CNS Neurol. Disord., 1, 399-411.
27. PEREIRA, E.F., HILMAS, C., SANTOS, M.D., ALKONDON, M., MAELICKE, A. & ALBUQUERQUE, E.X. (2002). Unconventional ligands and modulators of nicotinic receptors. J. Neurobiol., 53, 479-500.
28. QUICK, M.W. & LESTER, R.A. (2002). Desensitization of neuronal nicotinic receptors. J. Neurobiol., 53, 457-478.
29. REID, R.T. & SABBAGH, M.N. (2003). Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro. J. Alzheimers Dis., 5, 429-436.
30. RIDLEY, D.L., PAKKANEN, J. & WONNACOTT, S. (2002). Effects of chronic drug treatments on increases in intracellular calcium mediated by nicotinic acetylcholine receptors in SH-SY5Y cells. Br. J. Pharmacol., 135, 1051-1059.
31. RIDLEY, D.L., ROGERS, A. & WONNACOTT, S. (2001). Differential effects of chronic drug treatment on alpha3* and alpha7 nicotinic receptor binding sites, in hippocampal neurones and SH-SY5Y cells. Br. J. Pharmacol., 133, 1286-1295.
32. SALLETTE, J., BOHLER, S., BENOIT, P., SOUDANT, M., PONS, S., LE NOVERE, N., CHANGEUX, J.P. & CORRINGER, P.J. (2004). An extracellular protein microdomain controls up-regulation of neuronal nicotinic acetylcholine receptors by nicotine. J. Biol. Chem., 279, 18767-18775.
33. SAMOCHOCKI, M., HOFFLE, A., FEHRENBACHER, A., JOSTOCK, R., LUDWIG, J., CHRISTNER, C., RADINA, M., ZERLIN, M., ULLMER, C., PEREIRA, E.F., LUBBERT, H., ALBUQUERQUE, E.X. & MAELICKE, A. (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther., 305, 1024-1036.
34. SANTOS, M.D., ALKONDON, M., PEREIRA, E.F., ARACAVA, Y., EISENBERG, H.M., MAELICKE, A. & ALBUQUERQUE, E.X. (2002). The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol. Pharmacol., 61, 1222-1234.
35. SCHRATTENHOLZ, A., PEREIRA, E.F., ROTH, U., WEBER, K.H., ALBUQUERQUE, E.X. & MAELICKE, A. (1996). Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol., 49, 1-6.
36. SCOTT, L.J. & GOA, K.L. (2000). Galantamine: a review of its use in Alzheimer's disease. Drugs, 60, 1095-1122.
37. SHARPLES, C.G., KAISER, S., SOLIAKOV, L., MARKS, M.J., COLLINS, A.C., WASHBURN, M., WRIGHT, E., SPENCER, J.A., GALLAGHER, T., WHITEAKER, P. & WONNACOTT, S. (2000). UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J. Neurosci., 20, 2783-2791.
38. SVEDBERG, M.M., BEDNAR, I. & NORDBERG, A. (2004). Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase. Neuropharmacology, 47, 558-571.
39. VAUGHAN, P., PEERS, C. & WALKER, J.H. (1997). The regulation of noradrenaline release by receptors and second messengers in the human neuroblastoma clone SH-SY5Y. Curr. Top. Neurochem., 1, 195-209.
40. VAUGHAN, P.F., KAYE, D.F., REEVE, H.L., BALL, S.O. & PEERS, C. (1993). Nicotinic receptor-mediated release of noradrenaline in the human neuroblastoma SH-SY5Y. J. Neurochem., 6, 2159-2166.
41. WANG, F., GERZANICH, V., WELLS, G.B., ANAND, R., PENG, X., KEYSER, K. & LINDSTROM, J. (1996). Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits. J. Biol. Chem., 271, 17656-17665.
42. WHITEAKER, P., SHARPLES, C.G. & WONNACOTT, S. (1998). Agonist-induced up-regulation of alpha4beta2 nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition. Mol. Pharmacol., 53, 950-962.
43. WILCOCK, G.K., LILIENFELD, S. & GAENS, E. (2000). Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ, 321, 1445-1449.
44. WINBLAD, B. & JELIC, V. (2004). Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis. Assoc. Disord., 18 (Suppl 1), S2-S8.
45. WOODRUFF-PAK, D.S., VOGEL III, R.W. & WENK, G.L. (2001). Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc. Natl. Acad. Sci. U.S.A., 98, 2089-2094.